Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX for Masseter Muscle Prominence Phase 2b
NCT03861936Phase 2Completed
- Sponsor
- Allergan
- Start
- May 2019
- Primary completion
- Apr 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of onabotulinumtoxinA in masseteric hypertrophy (MH) (3 arms), sponsored by Allergan. Primary endpoint: Percentage of Participants Who Achieved Masseter Muscle Prominence Scale (MMPS) Grade ≤ 3 at Day 90. Started May 2019; status: completed.
02
Drugs
onabotulinumtoxinA
03
Conditions
masseteric hypertrophy (MH)
Beyond the preview
Go deeper on NCT03861936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03861936.